Creon 40,000 (pancreatin) unavailable

Exocrine pancreatic insufficiency is commonly caused by chronic pancreatitis or cystic fibrosis. | SCIENCE PHOTO LIBRARY
Exocrine pancreatic insufficiency is commonly caused by chronic pancreatitis or cystic fibrosis. | SCIENCE PHOTO LIBRARY

The pancreatic enzyme replacement therapy Creon 40,000 (pancreatin) is currently unavailable, owing to manufacturing difficulties.

The manufacturer, Abbott, recommends switching patients from Creon 40,000 to Creon 25,000, which will result in a lower pill burden than switching patients to Creon 10,000.

The supply issue is due to the biologic nature of Creon 40,000 and lower-than-expected concentrations of enzymes in porcine glands needed to produce the product. It is not related to any safety issue.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more